FDA Clears Novartis’ TOBI Podhaler With Post-Market Trials To Address Efficacy Concerns
This article was originally published in The Pink Sheet Daily
Executive Summary
Company also has to validate its instructions for use of the inhaled product for CF patients with Pseudomonas aeruginosa and determine if tobramycin resistance increases.